Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome

Abstract

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.

What is claimed is: 
     
         1 . A method of treating, preventing, reducing the risk of, delaying the onset or slowing the progression of albuminuria or diabetic nephropathy in a human type 2 diabetes patient with inadequate control of albuminuria despite therapy with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), said method comprising administering linagliptin in a daily oral amount of 5 mg in combination with the angiotensin-converting enzyme (ACE) inhibitor or the angiotensin II receptor blocker (ARB) to the patient. 
     
     
         2 . The method according to  claim 1 , wherein the patient is further administered with or without a glucose-lowering background therapy. 
     
     
         3 . A method of preventing, reducing the risk of or delaying the onset or progression of micro- or macro-albuminuria, the onset of chronic kidney disease (CKD), the worsening of CKD, the onset of acute renal failure or death in a human type 2 diabetes patient, said method comprising administering linagliptin in a daily oral amount of 5 mg to the patient. 
     
     
         4 . A method of treating albuminuria in an elderly human patient having type 2 diabetes and diabetic nephropathy, said method comprising administering linagliptin in a daily oral amount of 5 mg to the patient. 
     
     
         5 . The method according to  claim 4 , for lowering urinary albumin-to-creatinine ratio (UACR). 
     
     
         6 . The method according to  claim 4 , wherein the patient has renal impairment. 
     
     
         7 . The method according to  claim 4 , wherein the patient is further administered with or without a glucose-lowering background therapy and/or with or without ACE inhibitor or ARB therapy. 
     
     
         8 . The method according to  claim 4 , wherein the patient is aged 65 years.